Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 581 MAD study in healthy subjects and schizophrenia
NCT02504476Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMG 581 in schizophrenia and schizoaffective disorder (9 arms), sponsored by Amgen. Primary endpoints: Reported treatment-emergent adverse events at 39 days, Changes in systolic/diastolic blood pressure at 39 days and 9 more. Started Aug 2015; status: completed.
02
Drugs
AMG 581
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02504476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504476.